Edition:
India

Bill Berkrot

Jeff Mason is a White House Correspondent for Reuters and the 2016-2017 president of the White House Correspondents’ Association. He was the lead Reuters correspondent for President Barack Obama's 2012 campaign and interviewed the president at the White House in 2015. Jeff has been based in Washington since 2008, when he covered the historic race between Obama, Hillary Clinton and John McCain. Jeff started his career in Frankfurt, Germany, where he covered the airline industry before moving to Brussels, Belgium, where he covered the European Union. He is a Colorado native, proud graduate of Northwestern University and former Fulbright scholar.

Twitter handle: @jeffmason1

16 Apr 2018

Survival data boosts Merck's Keytruda lead in lung cancer

NEW YORK/CHICAGO Merck & Co's immunotherapy Keytruda plus chemotherapy significantly improved overall survival in newly-diagnosed patients with advanced non-small cell lung cancer in a closely-watched study, cementing its lead position over Bristol-Myers Squibb Co and others in the most lucrative oncology market.

16 Apr 2018

Merck, Bristol-Myers immunotherapies impress in key lung cancer trials

Merck & Co's immunotherapy Keytruda plus chemotherapy significantly improved overall survival versus chemotherapy alone in newly-diagnosed patients with advanced non-small cell lung cancer in a highly-anticipated study that appears to cement the company's lead in the most lucrative oncology market.

14 Apr 2018

EpiPen shortages seen in Canada, UK but U.S. supply intact

NEW YORK Mylan N.V.'s emergency allergy antidote EpiPen is in short supply in Canada and Britain, but remains available in the United States, the treatment's manufacturer said on Friday.

03 Apr 2018

High-flying biotech Loxo tempers bullish view for cancer drug

STAMFORD, Connecticut In record time, Loxo Oncology developed a novel drug for a wide variety of tumors that share a rare mutation. It recently struck a partnership with Germany's Bayer . Its stock tripled in the past year.

03 Apr 2018

U.S. government sets 3.40 percent hike in 2019 payments to Medicare insurers

The U.S. government on Monday said it would increase by 3.40 percent on average 2019 payments to the health insurers that manage Medicare Advantage insurance plans for seniors and the disabled, a higher-than-expected rise reflecting a projection of higher medical cost growth.

10 Mar 2018

Regeneron/Sanofi heart drug succeeds in major trial; Will insurers pay?

A potent, expensive cholesterol drug sold by Regeneron Pharmaceuticals and Sanofi significantly reduced major adverse heart events in a huge study presented on Saturday but it remains to be seen whether the new data will prompt insurers to pay for increased use of the medicine.

10 Mar 2018

Regeneron/Sanofi offer new Praluent pricing to break reimbursement logjam

Regeneron Pharmaceuticals Inc and Sanofi SA said on Saturday they would be willing to charge less for their potent cholesterol drug, Praluent, if insurers agree to lessen onerous access barriers for high-risk patients.

10 Mar 2018

Regeneron/Sanofi heart drug succeeds in major trial; Will insurers pay?

March 10 A potent, expensive cholesterol drug sold by Regeneron Pharmaceuticals and Sanofi significantly reduced major adverse heart events in a huge study presented on Saturday, but it remains to be seen whether the new data will prompt insurers to pay for increased use of the medicine.

09 Mar 2018

Eisai clinches Merck deal to develop and sell cancer drug, shares soar

(This March 8 story has been corrected to show in the 7th paragraph that Merck will pay, not receive, R&D reimbursement)

16 Feb 2018

U.S. FDA looks to pave way for earlier-stage Alzheimer's drugs

U.S. regulators have proposed lowering the bar for clinical trial success for experimental Alzheimer's drugs to better align with the current emphasis on the need to treat people when they are in the earliest stages of the brain-wasting disease.

Markets

  • Asia
  • U.S.
  • Europe
  • Sectors
Stock Search
Sensex 34,415.58 -11.71 -0.03%
Nikkei 22,162.24 -28.94 -0.13%
Hang Seng 30,418.33 -290.11 -0.94%
EUR/INR 81.201 -0.17%
USD/INR 66.200 +0.00%
GBP/INR 92.687 -0.08%
Gold 1,336.70 +0.00 +0.00%
Oil 68.40 +0.00 +0.00%
Corn 376.50 +0.00 +0.00%